GH250117P36000
- 1.53
- -0.27-15.00%
Guardant Health Newsroom
Jefferies Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $42
Jefferies Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $42
Piper Sandler Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $34
Morgan Stanley Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $42
Scotiabank Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $47
A Quick Look at Today's Ratings for Guardant Health(GH.US), With a Forecast Between $34 to $60
Guardant Health (GH) Gets a Buy From Scotiabank
Guardant Health Price Target Raised to $50.00/Share From $48.00 by JP Morgan
Guardant Health Is Maintained at Buy by Goldman Sachs
Stifel Nicolaus Remains a Buy on Guardant Health (GH)
BTIG Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $50
Piper Sandler Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $34
TD Cowen Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $42
Guardant Health: Strong Financial Performance and Growth Prospects Lead to Buy Rating
Morgan Stanley Maintains Guardant Health(GH.US) With Buy Rating, Cuts Target Price to $42
Bernstein Maintains Outperform on Guardant Health, Lowers Price Target to $35
Craig-Hallum Maintains Guardant Health(GH.US) With Buy Rating
Craig-Hallum Keeps Their Buy Rating on Guardant Health (GH)
Guardant Health Is Maintained at Outperform by Leerink Partners
Guardant Health Analyst Ratings